8047#Background:The Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Consortium (MYLUNG) program seeks to identify and resolve barriers to biomarker testing in patients (pts) with non-small-cell lung cancer (NSCLC). We previously reported prospectively collected ...
Predictive biomarker testing for programmed cell death 1 inhibition in Non-small cell lung cancer (ID 1081). Denver: 2015 World Conference on Lung Cancer; 2015. 40. Mitchell P, Murone C, Asadi K, Harbison CT, Knight S, John T. Programmed Death Ligand-1 (PDL-1) expression in Non-Small...
Notably, the field of targeted therapy for patients with lung cancer is rapidly evolving, so it is important to be in close communication with multidisciplinary experts to determine the optimal treatment for a patient, says Boyle. Additionally, biomarker testing should be supported so that tumor int...
Salman R. Punekar, MD, discusses the importance of complete biomarker testing and the landscape of biomarkers in lung cancer.
Despite significant improvements in the perception of biomarker testing compared to a 2018 survey, substantial barriers to implementation persist globally, according to results of the 2024 IASLC Global Survey on Biomarker Testing released today at the In
Biomarker-Driven Lung Cancer BRAIN CANCER BREAST CANCERBREAST CANCER GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS GENOMIC TESTINGGENOMIC TESTING GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS HEAD & NEC...
Hear Kerstin, a lung cancer patient from Austria, talk about her experience with biomarker testing: MA-LAR-ALL-0472-1 Physician Perspectives Hear Dr Vail, Director of Molecular Pathology at Cedars-Sinai Medical Center, explain biomarker testing: ...
Garrido P, de Castro J, Concha A, Felip E, Isla D, Lopez-Rios F, Paz-Ares L, Ramirez J, Sanz J, Gomez JJ (2012) Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncol- ogy (SE...
“Retrospective studies like this help us understand where we are as far as testing behaviors, while also identifying gaps in the data that need to be filled with the prospective research the MYLUNG Consortium will address in the next protoc...
The substantial benefit reported with adjuvant osimertinib (Tagrisso) in patients with EGFR-mutated non–small cell lung cancer (NSCLC) in the phase 3 ADAURA trial (NCT02511106) has underscored the need for biomarker testing in the post-resection setting, according to Jay M. Lee,...